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Abstract

Past research and case studies have shown that chemotherapy drugs appear to
lessen the quality of friction ridge skin, thereby impacting cancer patients who are
already experiencing a number of unpleasant side effects. Palmar-plantar
erythrodysaesthesia, more commonly referred to as Hand-Foot Syndrome (HFS), is a
common side effect of many chemotherapy agents and includes redness, swelling, and
peeling of the skin of the hands and feet. This syndrome has been linked to a number of
cases involving fingerprint loss, including a prior longitudinal study that evidenced
degradation in response to capecitabine, a common chemotherapy agent. This research
builds upon the prior study by assessing the effects of taxane class drugs and doxorubicin
on the fingerprints. Impressions were collected from seven patients, five of which were
prescribed taxane class drugs, and two of which were administered doxorubicin. Data
was collected prior to treatment and at the three-month mark, which represents the
halfway point of the general six-month administration cycle. Impressions were inputted
into AFIX Tracker software to determine the number of minutiae points by way of the
Smart-Extract feature. The data suggests no definitive decrease between taxane class
drugs and the quality of the impressions. A singular patient who had been prescribed
doxorubicin, however, experienced quality decrease, and may have been affiliated with
HFS. No other significant HFS was discovered with any of the patients, which further
certifies the link between HFS and ridge degradation.

Keywords: Friction ridge skin, Chemotherapy, Hand-Foot Syndrome, AFIX Tracker
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Chapter 1—Introduction
Exclusivity of Friction Ridge Skin
Fingerprint impressions are unique to each individual, allowing for an efficient
mode of identification. In a medical context, the degradation of these impressions has the
capacity to negatively impact patient quality of life. A reduced impression quality would
also lessen the efficiency of this method of identification, which may create significant
issues for patients who must provide their fingerprints for business or traveling purposes.
Past research suggests a correlation between chemotherapy drugs and a reduced quality
of friction ridge skin. By determining degradation factors, medical professionals may be
alerted to needed adjustment of treatment plans or, in the very least, may be provided
definitive side effect information for patient notification.
Prior Research Initiatives
Various research studies have associated capecitabine, a relatively common
chemotherapy drug, to ridge degradation, and in extreme cases, lack of ridge detail. The
majority of articles were written in response to individuals who were discovered to have
no ridge detail when asked to provide identification for traveling purposes.1, 2 After
subsequent investigation, all reported cases were chemotherapy patients who had been
prescribed capecitabine. Based on this data, a longitudinal study was conducted to isolate
the effects of capecitabine on a chemotherapy patient throughout the treatment process.
The results showed a direct relationship between capecitabine and ridge degradation, with
ridge detail returning to relatively normal levels approximately 65 days following
cessation of treatment.3

1

Distinctiveness of Study and Brief Methodology
This study will build upon a prior study through an assessment of the effects of
multiple chemotherapy drugs on impression quality. The study analyzed levels of
degradation, or lack thereof, in relation to drug class and treatment cycle. It also
correlated reduced ridge visibility with age, dosage, frequency of treatment, history of
treatment, and physical activities, all of which may promote research implications. Data
was collected from chemotherapy patients who have been prescribed the aforementioned
drug types at the University of South Alabama Mitchell Cancer Institute in Mobile,
Alabama.
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Chapter 2—Literature Review
Skin Layers
Throughout the litigation process, evidence that is dependable, such as the
exclusivity of a fingerprint, augments the position on which a case is founded.
Fingerprint impressions, more commonly referenced in forensic science as friction ridge
skin, are unique to every individual. Their uniqueness is based upon fundamental
biological principles of the skin. Friction ridge skin is grounded in the dermis, the second
of three skin layers.4 The outer layer of skin, the epidermis, functions primarily as a
barrier between lower levels of tissue and foreign substances in the surrounding
atmosphere. Though the epidermis is made up of a multitude of cell types, all of which
serve a specialized function, keratinocytes are the primary type of cell in the epidermis,
constituting 90-95 percent of the layer.5
Figure 1.1 illustrates the five layers
of keratinocytes characteristic of the
epidermis of the hand. Each layer is
distinct based upon cellular structure
and rigidity. As cells in the basal
layer undergo mitosis and are
Figure 1 Keratinocyte Layers 4

propelled upward, the cells gradually

harden.4 This process, known as keratinization, involves the production of the protein
keratin, a fortifying cellular agent required to manage the daily strain sustained by the
epidermis. Fully differentiated layers are sloughed off at the surface, creating a
continuous balance of production, keratinization, and depletion.4
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The dermis is the second skin layer, serving as a structural foundation for the
epidermis and a regulation site for temperature and sensory reaction.4 Eccrine sweat
glands, which primarily regulate body temperature, originate in the dermis or
hypodermis, dependent on their length, and extend to the surface of friction ridge skin.4
Also rooted in the dermis are subjacent projections of tissue, that correspond to the peaks
and valleys of a fingerprint pattern. Primary ridges support the “peaks” of a fingerprint,
while secondary skin ridges support the “valleys” of a given pattern.
Beneath the dermis lies the hypodermis, which is made up of flexible, fatty tissue.
The hypodermis provides for skin contouring and is composed of adipose tissue that
stores lipids for energy production.5
Formation of Friction Ridge Patterns and Minutiae
The singularity of friction ridge skin is the
result of natural biological development.
During gestation, friction ridge skin is
formed between 10.5 and 16 weeks.4 The
fundamental concepts of cell
proliferation and volar pad development
determine the construction of unique
friction ridge skin.4 Volar pads form as a

Figure 2 Volar Pad Development 6

result of inflammation of the tissue beneath the epidermis. This swelling of tissue begins
at the thumb at approximately 7 weeks, as depicted in Figure 1.26, and slowly progresses
to each adjacent finger.4 After eleven weeks, the volar pads begin to change shape as
cells present in surrounding tissue rapidly divide and combine with volar pad tissue. This
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process yields a recognizable delineation of the hand and fingers at approximately 16
weeks.7
The foremost theory of ridge formation holds that basal cells in the epidermis
rapidly divide at approximately 10.5 weeks.8 Cell groupings join together and develop
into randomized patterns.4 Figure 1.36 illustrates this theory. As each finger increases in
size, the ridges that have developed are distanced, and additional ridges form to fill in the
space.11
The cell’s ability to fill in space in order
to maintain consistency corresponds to
minutiae formation. Minutiae, or distinct
locales present on friction ridge skin, create
distinction between fingerprint impressions.
Essentially, minutiae are variations of ridge
structure and fall under two distinct
categories: ridge endings and bifurcations.12
In addition to the minutiae present on
Figure 3 Formation of Friction
Ridge Skin 6

friction ridge skin, each impression can be

divided into one of three classes of ridge patterns: loops, whorls, and arches, all of which
are dependent on volar pad size and regression behavior.4 In summary, the height of the
volar pad and the shape it takes as surrounding areas of tissue begin to slowly grow may
affect the size and orientation of the pattern.4, 13-15 Loops are the most common type of
pattern, occurring in approximately 60 percent of the population. They originate from one
side of the print, curve around, and continue toward the side from whence it originated.16,
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Whorls are circular in shape, and are the second most common type of pattern,

occurring in approximately 35 percent of the population.17 The last pattern type, arches,
are the least common pattern, with a 5 percent occurrence in the population. Arches begin
on one side of the print and exit on the opposite side.16,17 Loops, whorls, and arches can
be classified according to two points, known as core and delta points. Core points are the
approximate center of a pattern, or the location at which central ridges are at their
steepest. Each pattern has a core. A delta can be defined as the point at which ridges
diverge. Loop patterns have one delta, while whorl patterns have two deltas.16
Case Report Studies Depicting Hand-Foot Syndrome
This research study measured the degradation, or lack thereof, of ridge detail in
conjunction with drug class and treatment cycle. Additional medical history that may
account for degradation, including age, dosage, frequency of treatment, past history, and
physical activities will also be observed. As previously denoted, each individual has
unique friction ridge skin. In a medical context, the degradation or loss of friction ridge
skin adversely affects patients whose quality of life has already been diminished.
According to Al-Ahwal (2012), clinicians should place greater focus on the potential loss
of ridge detail, which could add significantly more stress to cancer patients whose lives
have already been severely altered.2 The author describes the case report of a 53-year old
male patient diagnosed with stage IV adenocarcinoma metastasized to the liver, lungs,
and rectum.2 As part of a palliative care regimen, the patient was administered
capecitabine, an anti-metabolic drug that prevents the growth of cancer cells by inhibiting
DNA and RNA production.18 After fifteen days of treatment, the patient presented with
grade 1 Hand-Foot Syndrome (HFS) following the second and third cycles of
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chemotherapy. Following the fifth and sixth chemotherapy administration cycles, the
patient exhibited grade 3 HFS and fingerprint loss.2
Hand-Foot Syndrome, scientifically referred to as palmar-plantar
erythrodysesthesia (PPE), is a common adverse response to chemotherapy drug
administration. HFS manifests as erythema (reddening) and dysesthesia (numbing
sensation) localized to the palms of the hands and the soles of the feet. Patients with
severe cases of HFS present with swelling and blistering of the skin accompanied by
desquamation (the shedding of skin layers).9 The National Cancer Institute classifies HFS
into three grades that correspond to severity. Grade 1 HFS is characterized as erythema
with no pain or discomfort; Grade 2 HFS presents as skin peeling, blistering, and
bleeding accompanied by edema (fluid build-up); Grade 3 HFS most significantly affects
routine activities and is characterized as ulceration in addition to previous grade
symptoms.10
A separate report, published by Wong, Choo, and Tan, presents the case of a 62year old male patient diagnosed with metastatic nasopharyngeal carcinoma. Following
treatment, doctors placed the patient on a capecitabine regimen in July 2005 to sustain
remission status.1 After follow-up appointment, the patient was prescribed a continuation
of the dosage. In December 2008, three years following the initial capecitabine treatment,
airport officials were unable to locate ridge detail, and the patient was detained for
several hours at airport customs and impeded from entering the country.1 The authors’
note that many patients who undergo long-term capecitabine administration may
experience loss of prints and should be notified to avoid inconvenience.1
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Capecitabine and Ridge Degradation
Capecitabine, or Xeloda, is an anti-metabolic drug that is orally administered to
catalyze the effects of Fluorouracil, a substance that prevents cancerous growth by
inhibiting DNA and RNA production.19 Without DNA and RNA, cells are unable to
properly function and reproduce. Though the prevalence of HFS is markedly higher with
capecitabine administration, there are additional drugs associated with HFS. The
following are examples of drugs that have been cited with HFS symptoms: Cytaribine,
Floxuridine, Fluorouracil, Idarubicin, Liposomal doxorubicin, Doxorubicin, Sunitinib,
Sorafenib, Pazopanib, and Vemurafenib.3
The developmental process of capecitabine-induced HFS is currently being
studied.3, 20, 22-24 Current hypotheses on the subject speculate that both cancerous and
epidermal cells are susceptible to the toxic effects of capecitabine.3 Other hypotheses
suggest changes in the skin occur when small amounts of chemotherapy seep out of the
blood vessels in the extremities and are introduced to surrounding tissue.3 Still other
hypotheses suggest that chemotherapy drugs, like excess water and salts, are emitted
from the body as waste products by way of pores that are linked to eccrine sweat glands.
3, 25

Several of these hypotheses appear to be plausible based on the conversion
process of Fluorouracil into an effective cancer targeting substance.3, 5 The introduction
of capecitabine into the system causes numerous reactions to take place, leading to the
eventual conversion of Fluorouracil to 5-FU.3 Specifically, the enzyme thymidine
phosphorylase, or TP, aggregates at cancerous sites in large quantities and converts
Fluorouracil to 5-FU, thereby limiting its toxic effects to cancerous tissue.19 Studies have
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shown that TP is more prevalent in friction ridge skin than other areas of the body,
suggesting that the increased proliferation of keratinocytes in the epidermis draws 5-FU
to these areas in much the same way that the substance is drawn to areas with high
proliferation of cancerous cells.3, 19
Longitudinal Study of Ridge Degradation
A longitudinal study conducted by Schenck documented the effects of
capecitabine on a single patient from initial administration to final treatment.3 The study
evidenced diminished friction ridge skin in relation to capecitabine administration. The
study also attested to the permanency of friction ridge skin; though ridges were exposed
to toxic medication, detail was restored to close to initial condition approximately 65
days after treatment, with no change in pattern or minutiae arrangement.3 These results
are depicted in Figure 1.4. Section “A” displays quality of ridge detail at the beginning of
treatment, “B” showcases the quality throughout duration of treatment, “C” is indicative
of quality at cessation of treatment, and “D” signals the return of normal ridge detail. The
study evidences a direct result between capecitabine and a decline in impression quality.3
These findings verify previous literature that estimates keratinocyte maturation to be
between 30 to 40 days.6 The decline of observed quality correlates to a significant
disruption in basal layer proliferation, suggesting that these rapid areas of growth were
susceptible to 5-FU in much the same way as cancerous growth and required
approximately 30 to 40 days for friction ridge detail to be apparent on the upper
epidermal layer.3
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Figure 4 Longitudinal Study Results: Ridge Quality in Relation to Cycle of Treatment 3
The author challenges researchers to build upon this research initiative by
documenting the results of varying capecitabine dosages as well as the effects additional
chemotherapy drugs on friction ridge detail.3 The present study addressed one portion of
this challenge, calling for observation of the effects of Taxane class drugs and
Doxorubicin on friction ridge skin.
Taxane Class Drugs and Anti-Microtubule Mechanism
Taxane class drugs are anti-microtubule reagents whose principle mechanism is
the stabilization of guanosine diphosphate (GDP)-bound tubulin in the microtubule.26 The
protein tubulin polyermizes in vitro to form microtubules, or fibrous cellular projections
that support cellular activity, including spindle fiber formation during mitosis.27 Many
anti-microtubule reagents stop cellular growth by preventing polymerization; however,
taxane class drugs operate with a reverse mechanism. Taxane class drugs inhibit mitosis
by binding to tubulin and preventing it from depolymerizing.30 In summary, once spindle
fibers are formed, taxane class drugs prevent the fibers from decreasing in size, and
therefore, prohibit chromosomes from separating, a crucial step in mitosis.
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Taxane drugs, derived from the plant genus Taxus, include Paclitaxel (Taxol) and
Docetaxel (Taxotere).26 These drugs are administered by injection, with common side
effects including swelling, rash, and painful separation of the nail from the nail bed.26
HFS is a reported side effect of taxane class drugs, with paclitaxel at a ten percent
occurrence and docetaxel at a five percent occurrence.26, 28-29 Taxane-induced HFS is
reported more frequently with relatively large doses that are administered in quick
succession.26
Several case reports detail both paclitaxel and docetaxel-induced HFS.30,31 The
first case report details a 72-year old patient diagnosed with stage T1 breast cancer and
prescribed a weekly injection of paclitaxel over a span of twelve weeks.30 Following the
sixth dosage of paclitaxel, the patient was diagnosed with grade 3 HFS, characterized by
redness, desquamation, and dysesthesia. The patient was instructed to wear long articles
of clothing and generously apply sun block to the affected areas, which yielded
improvement and continuation of the 12-week treatment.30 The second and final case
report details a 52-year old patient diagnosed with metastatic breast carcinoma. The
patient was administered two weekly cycles of docetaxel, after which, the patient
presented with grade 3 HFS characterized by severe redness and swelling.31 Although the
patient was prescribed a dosage that has not presented HFS in the past, professionals are
certain that the patient’s metastatic condition altered metabolism of the drug, causing
symptoms at a lower dosage.31 Despite the incidence of HFS, no reports exist describing
the potential effect of taxane drugs on friction skin ridges.
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Liposomal Doxorubicin (Doxil) and Anthracycline Mechanism
Liposomal Doxorubicin, or Doxil, is an antitumor anthracycline, a drug class
derived from the Streptomyces fungus species. The drug is composed of doxorubicin
encased in a liposome, or lipid, to allow for direct contact with cancerous tumor growths
upon injection without detection by the immune system.32 Though the exact targeting
mechanism of the drug is currently unclear, scientists Denard, Lee, and Ye of the
University of Texas Southwestern (UTSW) Medical Center have contributed to research
on this subject. Their research evidences that a viral infection prompts the detachment of
a protein, CREB3L1, and its corresponding amine group from the cellular membrane.
The protein and amine travel to the nucleus, where genetic code is transcribed, including
code that inhibits cellular proliferation.33, 34 The UTSW group has found that doxorubicin
prompts the formation of lipid molecules known as ceramides, which aid in detaching
CREB3L1 from the membrane.33, 35 Though the exact mechanism of cellular breakdown
by doxorubicin is unclear, these findings provide information that can be built upon
through further analysis.
There are several noted changes in the skin as a result of doxorubicin
administration; HFS is a common side effect of doxorubicin, occurring five to six weeks
following treatment in approximately 30 percent of cases. In approximately 10 to 29
percent of all patients, the drug darkens and discolors the nail bed. 32
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Chapter 3—Methodology
Overview of Academic Partnership and Objectives
Collection of fingerprints took place in the Chemotherapy Infusion Suite of the
University of South Alabama Mitchell Cancer Institute (USAMCI), located at 1660
Springhill Avenue in Mobile, Alabama. Michael A. Finan, M.D., Director of the Mitchell
Cancer Institute, and Dr. Rodney P. Rocconi, M.D., Associate Director for Clinical
Research, agreed to a research partnership with the University of Southern Mississippi’s
School of Criminal Justice following in tandem approval of the University of Southern
Mississippi and South Alabama Internal Review Boards. Dr. Jenna Wildman, a resident
enrolled in the University of South Alabama College of Medicine, and Lynley Walsh, a
nurse at the Mitchell Cancer Institute, assisted with data collection.
Primary objectives of study protocol were to conduct a study of the effects of
taxane class drugs and liposomal doxorubicin on friction ridge skin. Principal aims
included sharing data with USAMCI in order to provide essential information for patient
notification. Secondary objectives included analysis of treatment plans and prior medical
history in conjunction with generated quality scores to determine statistical trends.
Study Population
Partnership with USAMCI was utilized to identify seven patients who had been
prescribed taxane class drugs or liposomal doxorubicin. Specifically, five patients were
enrolled in the study who were administered taxane class drugs and two participants who
were administered doxorubicin. Though the original proposed study aimed for a larger
study population, the population was limited in order to be conducive to time constraints.
Chemotherapy combinations containing the studied drugs were admitted to the study and
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additional drugs present were noted. After all patients were admitted to the study, ridge
detail impressions were collected for further analysis and interpretation.
Data was collected upon diagnosis and at the halfway point of treatment (3
months). This research initiative was classified as a pilot study that the researcher intends
to build upon in the future. The researcher aims to gather impressions throughout the
entire chemotherapy treatment period that typically lasts 6 months. Impressions were
gathered prior to the first chemotherapy cycle, at the halfway point (3 months), and will
be gathered at completion of chemotherapy (6 months). Additionally, a postchemotherapy impression will be obtained to assess resolution of ridge detail at 90 days
+/- 14 days. These impressions will only be gathered in the event that the data evidences
definitive degradation.
Exclusion criteria included individuals who were not prescribed taxane class
drugs or doxorubicin. No individual who met inclusion criteria was excluded from the
study due to race, ethnicity, socioeconomic status, or gender. Patients were provided with
a consent form and were informed of their rights to refuse participation. Prior to
collection and at the discretion of the guidelines for Human Subjects Research and the
researcher, all probable participants demonstrated an understanding of the extent of the
study, including any and all potential benefits and harm. All consent forms were signed
prior to data collection.
Research Design
Friction ridge skin impressions were collected utilizing the powder/label
technique.36 A relatively common postmortem lift technique, this method showcases
clearer ridge detail in comparison to the traditional ink method, as indicated in Figure
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1.5.36 The powder/label technique
necessitates the direct application of
black fingerprint powder to the skin by
a fingerprint brush. Following the light
coating of powder onto the skin, the
adhesive side of a white mailing label
Figure 5 Comparison of Powder and Ink Lift
Methods 36
was slowly applied to one side of the
finger to reduce doubling the impression and was then flattened onto the remainder of the
finger.36 The label was applied to the backside of a clear acetate ten-print card,
correspondent to the appropriate finger from which the impression was collected. Residue
was cleaned from the skin using hand wipes.36
During the collection period, the researcher and all collaborators maintained a
central logbook in which patient name corresponded to a unique study identification
number. The logbook was stored at USAMCI in a locked cabinet with access provided
only by the clinical trial staff of the USAMCI. All investigators and clinical trial staff
had completed and maintained HIPPA training and certification. Dr. Wildman and
Lynley Walsh assisted with clinical data collection and was informed and educated of the
identification system, which remained prevalent throughout the study. When patient
information was needed, study identification numbers were provided via email to these
individuals, who provided the corresponding materials.
All clinical data was de-identified and maintained on a password-protected
spreadsheet on the researcher’s computer. All collected impressions were labeled with the
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study number and transported by the researcher back to the University of Southern
Mississippi School of Criminal Justice Fingerprint Laboratory for analysis.
Data Analysis and Interpretation
Collected data was analyzed using a scoring system existent in a database known
as AFIX Tracker.37 The software has the capability to allow for both comparison of a
collected print to a database and individual analysis of a single impression. The latter
capability was utilized and is referred to as the “Smart-Extract” feature, which assesses
impression quality by automatically identifying the number of minutiae points on a
particular print. This number is referred to as a quality score. Each individual set of ten
prints was scanned into the software and the scores of each finger recorded five separate
times in order to gather a more holistic data set.
Statistical analyses were performed to evaluate impression quality, impression
scores correlated to chemotherapy agents received and associated clinical factors, as well
as chemotherapy administration details such as dosage, length of chemotherapy duration,
and delays or reductions in chemotherapy. Additional variables include age of the patient,
prior history, and physical activities.
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Chapter 4—Results
To begin the study, 200 sets of fingerprint impressions from the AFIX Tracker
Database were selected at random and an average score for each finger was generated.
This was done in order to provide readers with a general understanding of the average
number of minutiae per finger with respect to normal quality and surface area. It should
be noted that the first scores refer to the right hand thumb, followed by the right index
finger, and so forth. The sixth score corresponds to the left hand thumb, followed by the
left index finger, and so forth. The results are shown in the Table 1.1 below.
Baseline Averages from AFIX
Tracker Database
Avg. 1
79.495
Avg. 2
59.525
Avg. 3
60.955
Avg. 4
50.270
Avg. 5
35.205
Avg. 6
81.950
Avg. 7
55.675
Avg. 8
58.845
Avg. 9
47.445
Avg. 10
34.705
Table 1 Baseline Averages from AFIX Tracker Database
After reviewing the taxane class drug data that corresponds to baseline and threemonth data, no definitive decrease in ridge quality was indicated. Although several of the
scores obtained from AFIX Tracker decreased, the researcher noted increases in ridge
quality as well, which is a testament to the surface area captured during collection and not
that of chemotherapy. Additional variables that may have affected scores included the
amount of powder applied, which causes slightly darker and lighter sections of an
individual print that make reading by a scanner difficult. Regardless of the variables
associated with decrease, it can be said that chemotherapy was not a variable to be
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accounted for. If all of the taxane class drug impressions collected at three months had
decreased, one could conclude that chemotherapy was a factor, but based on increases at
three months, the methodology itself must be cited as cause for both increase and
decrease. After examining the impressions directly, the researcher could find no marked
decrease in ridge visibility or marked increase in lines and creasing.
In contrast, one of the patients prescribed doxorubicin experienced significant
ridge degradation in each impression. The AFIX Tracker scores associated with this
participant are listed in Table 2 below. It should be noted that the first score corresponds
to the right hand thumb, followed by the right index finger, and so forth. The sixth score
from the top corresponds to the left hand thumb, followed by the left index finger, and so
forth.
Baseline AFIX Scores (1-10)
Three-Month Scores (1-10)
114
61.6
65.4
53.6
82.8
29.6
36.8
7
20.4
4.6
143.6
63.6
66.2
32.8
55.2
8.6
30.2
4
29.6
3.8
Table 2 Comparisons of Baseline and Three-Month Scores of Doxorubicin Patient
The researcher noticed significant decrease in ridge visibility in the majority of the
impressions as a result of increased creasing that obstructs ridges from view. After
meeting with the patient and a relative to collect data at the three-month mark, a comment
was made regarding the patient’s issue with HFS. Though the symptom was not
documented in the patient’s chart, a nurse verified that medical personnel rarely ask
patients questions regarding HFS.
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The scores associated with the final doxorubicin participant were similar to those
of the taxane class. There were both decreases and increases, which must be attributed to
surface area and technique, and not to chemotherapy. However, the researcher noted
slight decrease in ridge visibility, though AFIX was able to output increased scores.
Study participants were between 27 and 84 years of age and were administered
chemotherapy concoctions including paclitaxel and avastin, gemcitabine and docetaxel,
paclitaxel and carboplatin, doxil and avastin, and simply, doxil. It should be noted that
the patient following the gemcitabine and docetaxel regimen was prescribed a new set of
chemotherapy drugs that are not being researched in this study, and therefore, the
participant has been excluded from it.
For those administered taxane class drugs, dosages ranged from 144 mg weekly to
upward of 270 mg every three to four weeks. Patients prescribed doxil were administered
approximately 60 mg of the drug every month. Several patients had prior history with
these concoctions, while some patients have had reductions in dosage and changes in
medication. To briefly cite the research survey distributed among participants, there were
variations in physical activities and hobbies, including gardening and carpentry. Despite
the numerous differences in concoctions, dosage, medical history, and physical activities,
there was no definitive decrease in ridge detail for a majority of the study population.
Furthermore, past research indicates that HFS has presented in taxane class drugs
following the sixth weekly dosage of paclitaxel. Research on doxorubicin claims that
HFS is evidenced five to six weeks following treatment in approximately thirty percent of
cases. There was no evidence of the severe swelling, peeling, or blistering indicative of
HFS in any of the patients. Though no severities were noted, based on the interaction

19

with the doxorubicin patient who experienced degradation, HFS may very well have
presented at a lower grade.
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Chapter 5—Conclusion
Discussion of HFS Theories
It is quite clear based on prior research initiatives that all of the chemotherapy
drugs in question affect the human body in a way that is synonymous to cause HFS,
though the exact mechanism in which chemotherapy causes this syndrome is unknown.
The lack of both visible signs of HFS and corresponding fingerprint degradation does not
disprove that these two variables may be related.
There are a variety of theories that attempt to account for the mechanism of HFS.
There are also a number of ways in which chemotherapy targets cancerous growth. In
each mechanism, however, HFS has been cited in many cases. Dosage spacing of taxane
class drugs ranged from every week to every three to four weeks. After assessing the case
studies that evidenced HFS with respect to paclitaxel and docetaxel30-31, the researcher
found that patients diagnosed with HFS received smaller dosages of taxane class drugs
compared to study participants. Factors that may have influenced the presence of HFS
include the metabolism of the drug in relation to premedications and the rate at which the
drugs are administered.
In the case of doxorubicin, the research indicates that HFS occurs in thirty percent
of cases. In the research participants, dosages were administered every four weeks. Both
doxorubicin participants were administered similar dosages every four weeks, though the
patient who exhibited degradation was only administered doxil, as opposed to additional
chemotherapy concoctions. Similar inferences from taxane class drug actions may be
applied here as well; perhaps the drug brought about a decrease in ridge quality as a result
of an interaction distinct from the other doxorubicin patient.
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Study Limitations and Future Challenges
Due to time constraints pertaining to the study, there were only two individuals
enrolled who were prescribed doxorubicin. Enrolling additional patients on this drug
would have made for a more conclusive study, and therefore, more comprehensive data
in regards to percentages of disruption found in ridge detail.
An additional verification for contemplation includes the methodology itself,
specifically, the powder and label technique. Though research has shown that this
technique is sublime in comparison to the traditional ink technique, Figure 1.5 showcases
a larger surface area associated with the traditional technique, which may result in a
surface area consistency.
Perhaps most significantly, in order to prove or disprove theories that correlate
HFS to fingerprint loss, future researchers should consider collecting fingerprint
impressions at all grades of this syndrome to observe the presence or absence of ridge
detail. Additional variables to include in relation to HFS are the premedications
administered in relation to chemotherapy as well as the rate the chemotherapy is
administered.
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